• Monday - Thursday: 9.00 am - 6.00 pm

Now Recruiting

Dry Eye Disease Clinical Trial

A Phase 3 Multi-Centre, Randomised, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 µg/ml in Subjects Diagnosed with Dry Eyes.

Dry Eye Disease with Autoimmune Disease Clinical Trial

ILYX-002-201: A Multicenter, Randomized, Controlled, Double-Masked Phase 2 Trial of the Safety and Therapeutic Effects of ILYX 002 Versus Vehicle Control for Treatment of Dry-Eye Disease in Patients with Autoimmune Disease

In the OTA Pipeline – Please register your interest:

  • Post-market dry eye Phase IV clinical trial to assess the effectiveness of eye drops for dry eye on the market.
  • Chronic Ocular Surface Pain (COSP) greater than 6 months in duration with or without dry eye. This Phase II clinical trial is a device and in-clinic treatment with follow-up.
  • A Phase II Prospective Randomized Crossover Study Assessing the Acute Safety & Efficacy Of Investigational Product Compared to Vehicle for the Treatment of Sjögren’s Related Dry Eye Disease
  • Ocular Surface Discomfort in the setting of dry eye. A Phase II novel ocular surface analgesic/neuropathic pain modulator as an eye drop.  
  • A novel eye drop Phase II clinical trial for moderate to severe dry eye disease with ocular surface inflammation.
  • Dry eye disease Phase III trial in the setting of meibomian gland obstruction. Bi-weekly application of IP mitigating the primary cause of evaporative dry eye.

Our focus is on anterior eye, simply register your interest here and we will follow you up. 

To register your interest, email tracey@ot-au.com or call 07 3608 2074 and advise on which trial you are interested in.

Ophthalmic Trials Australia